Fortis Healthcare Limited – Investor Presentation Summary
Key Operational Highlights
- Hospital business occupied beds increased to 3,418 compared to 2,928 in Q1FY26, a growth of 16.7%.
- Occupancy for the quarter stood at 68.7% versus 69.0% in Q1FY26.
- ARPOB was at ₹2.71 Cr per annum vs ₹2.64 Cr in Q1FY26, up 2.6%.
- Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16.9% and contributed 62% to overall hospital business revenues.
- Revenues from digital channels witnessed an 18.2% YoY growth; contributed 29.2% to overall hospital revenues.
- International Patient revenues grew 13% to ₹174 Cr in Q1FY27 vs ₹154 Cr in Q1FY26, contributing 7.5% to hospital business revenues.
- Agilus Diagnostics conducted 10.46 Mn tests versus 10.13 Mn in Q1FY26.
- Agilus added 200+ Customer touchpoints to its network in Q1FY27.
- Agilus' B2C: B2B revenue mix stood at 53:47 in the quarter vs 51:49 in Q1FY26.
Key drivers of operational performance: Growth in occupied beds, expansion of diagnostic network, strong performance in focus specialties, and digital channel growth.
Segment-wise Performance
Hospital Business: Revenue of ₹2,187 Cr in Q1FY27 vs ₹1,838 Cr in Q1FY26 (19% growth). Operating EBITDA stood at ₹471 Cr (21.5% margin).
Diagnostics Business (Agilus): Gross revenue of ₹407 Cr in Q1FY27 vs ₹369 Cr in Q1FY26 (10.2% growth). Operating EBITDA stood at ₹97 Cr (23.9% margin).
Explanation of significant changes in segment performance: Hospital growth driven by increased occupied beds and specialty focus; diagnostics growth driven by network expansion and test volume increase.
Financial Highlights
Revenue: ₹2,545.0 Cr
EBITDA: ₹551.6 Cr
PAT: ₹272.8 Cr (from continuing operations)
EPS: Not Specified
Margins: EBITDA Margin 21.7%, Operating EBITDA Margin (ex-ESOP) ~21.5% for hospitals and 23.9% for diagnostics
YoY/QoQ comparison: Revenue up 17.5% YoY (₹2,166.7 Cr in Q1FY26); PAT from continuing operations up 2.3% YoY (₹266.8 Cr in Q1FY26)
Drivers of financial performance: Higher revenue growth across both hospital and diagnostics businesses
Comparison to market estimates: Not Specified
Key Risks: Not explicitly disclosed in presentation
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not Specified in detail
International Patient revenues: ₹174 Cr (7.5% of hospital business revenues)
Regional Breakdown: Not Specified
Balance Sheet Snapshot (Consolidated as of June 30, 2026)
Net Debt/Equity: 0.21x
Reserves: Not explicitly stated (Shareholder's Equity: ₹10,472 Cr)
Current Assets/Liabilities: Not Specified
Working Capital/Leverage Metrics: Net Debt to EBITDA was at 1.01x (basis annualized EBITDA of Q1FY27)
Financial Health Insights: Strong balance sheet with shareholder's equity of ₹10,472 Cr and net debt of ₹2,233 Cr
Capex & Cash Flow Health
Capital Expenditure: Not Specified for Q1
Free Cash Flow: Not Specified
Operating Cash Flow: Not Specified
Net Debt Movement: Net debt decreased to ₹2,233 Cr from ₹2,334 Cr as of March 31, 2026
Investment Rationale: Not explicitly stated, but balance sheet indicates capacity for strategic investments
Strategic & R&D Initiatives
Investments in Innovation: Advanced Da Vinci Xi Robotic Surgical Systems at Fortis Escorts Okhla and Faridabad; India's First Centre of Excellence for Myeloma & Lymphoma at Fortis Gurugram; Institute of Neurosciences at Fortis Noida
Expected impact on growth: Not quantified
Strategic Rationale: Enhancing clinical capabilities and offering comprehensive care in specialized areas
Industry Trends & Business Environment
Macro/Industry Trends: Not explicitly discussed
Impact on Company: Not Specified
Management Commentary & Growth Outlook
Strategic Outlook: Not explicitly provided in presentation
FY Guidance: Not Provided
Market Share Targets: Not Provided
Risks and Opportunities: Not highlighted
Clinical Excellence Highlights
- Fortis Escorts, Okhla Road conducted a 10-hour surgery to remove a rare 14.5 kg abdominal sarcoma tumor
- Fortis Hospital, Vasant Kunj successfully treated Walled-Off Pancreatic Necrosis through advanced robotic pancreatic necrosectomy
- Robotic surgical systems and specialized institutes launched to enhance medical capabilities